Dosimetric Comparison of 6 MV and 15 MV Single Arc Rapidarc to Helical TomoTherapy for the Treatment of Pancreatic Cancer

Jing Cai, Jinbo Yue, Robert McLawhorn, Wensha Yang, Krishni Wijesooriya, Neal E. Dunlap, Ke Sheng, Fang Fang Yin, Stanley H Benedict

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We conducted a planning study to compare Varian's RapidArc (RA) and helical TomoTherapy (HT) for the treatment of pancreatic cancer. Three intensity-modulated radiotherapy (IMRT) plans were generated for 8 patients with pancreatic cancer: one using HT with 6-MV beam (Plan_ HT6), one using single-arc RA with 6-MV beam (Plan_ RA6), and one using single-arc RA with 15-MV beam (Plan_ RA15). Dosimetric indices including high/low conformality index (CI 100%/CI 50%), heterogeneity index (HI), monitor units (MUs), and doses to organs at risk (OARs) were compared. The mean CI 100% was statistically equivalent with respect to the 2 treatment techniques, as well as beam energy (0.99, 1.01, and 1.02 for Plan_ HT6, Plan_ RA6, and Plan_ RA156, respectively). The CI 50% and HI were improved in both RA plans over the HT plan. The RA plans significantly reduced MU (MU RA6 = 697, MU RA15 = 548) compared with HT (MU HT6 = 6177, p = 0.008 in both cases). The mean maximum cord dose was decreased from 29.6 Gy in Plan_ HT6 to 21.6 Gy (p = 0.05) in Plan_ RA6 and 21.7 Gy (p = 0.04) in Plan_ RA15. The mean bowel dose decreased from 17.2 Gy in Plan_ HT6 to 15.2 Gy (p = 0.03) in Plan_ RA6 and 15.0 Gy (p = 0.03) Plan_ RA15. The mean liver dose decreased from 8.4 Gy in Plan_ HT6 to 6.3 Gy (p = 0.04) in Plan_ RA6 and 6.2 Gy in Plan_ RA15. Variations of the mean dose to the duodenum, kidneys, and stomach were statistically insignificant. RA and HT can both deliver conformal dose distributions to target volumes while limiting the dose to surrounding OARs in the treatment of pancreatic cancer. Dosimetric advantages might be gained by using RA over HT by reducing the dose to OARs and total MUs used for treatment.

Original languageEnglish (US)
Pages (from-to)317-320
Number of pages4
JournalMedical Dosimetry
Volume36
Issue number3
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Intensity-Modulated Radiotherapy
Pancreatic Neoplasms
Organs at Risk
Therapeutics
Duodenum
Stomach
Kidney
Liver

Keywords

  • Pancreatic cancer
  • RapidArc
  • Tomotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Dosimetric Comparison of 6 MV and 15 MV Single Arc Rapidarc to Helical TomoTherapy for the Treatment of Pancreatic Cancer. / Cai, Jing; Yue, Jinbo; McLawhorn, Robert; Yang, Wensha; Wijesooriya, Krishni; Dunlap, Neal E.; Sheng, Ke; Yin, Fang Fang; Benedict, Stanley H.

In: Medical Dosimetry, Vol. 36, No. 3, 2011, p. 317-320.

Research output: Contribution to journalArticle

Cai, Jing ; Yue, Jinbo ; McLawhorn, Robert ; Yang, Wensha ; Wijesooriya, Krishni ; Dunlap, Neal E. ; Sheng, Ke ; Yin, Fang Fang ; Benedict, Stanley H. / Dosimetric Comparison of 6 MV and 15 MV Single Arc Rapidarc to Helical TomoTherapy for the Treatment of Pancreatic Cancer. In: Medical Dosimetry. 2011 ; Vol. 36, No. 3. pp. 317-320.
@article{41d8f2be0b6d4ee499a134bf9c5ff591,
title = "Dosimetric Comparison of 6 MV and 15 MV Single Arc Rapidarc to Helical TomoTherapy for the Treatment of Pancreatic Cancer",
abstract = "We conducted a planning study to compare Varian's RapidArc (RA) and helical TomoTherapy (HT) for the treatment of pancreatic cancer. Three intensity-modulated radiotherapy (IMRT) plans were generated for 8 patients with pancreatic cancer: one using HT with 6-MV beam (Plan_ HT6), one using single-arc RA with 6-MV beam (Plan_ RA6), and one using single-arc RA with 15-MV beam (Plan_ RA15). Dosimetric indices including high/low conformality index (CI 100{\%}/CI 50{\%}), heterogeneity index (HI), monitor units (MUs), and doses to organs at risk (OARs) were compared. The mean CI 100{\%} was statistically equivalent with respect to the 2 treatment techniques, as well as beam energy (0.99, 1.01, and 1.02 for Plan_ HT6, Plan_ RA6, and Plan_ RA156, respectively). The CI 50{\%} and HI were improved in both RA plans over the HT plan. The RA plans significantly reduced MU (MU RA6 = 697, MU RA15 = 548) compared with HT (MU HT6 = 6177, p = 0.008 in both cases). The mean maximum cord dose was decreased from 29.6 Gy in Plan_ HT6 to 21.6 Gy (p = 0.05) in Plan_ RA6 and 21.7 Gy (p = 0.04) in Plan_ RA15. The mean bowel dose decreased from 17.2 Gy in Plan_ HT6 to 15.2 Gy (p = 0.03) in Plan_ RA6 and 15.0 Gy (p = 0.03) Plan_ RA15. The mean liver dose decreased from 8.4 Gy in Plan_ HT6 to 6.3 Gy (p = 0.04) in Plan_ RA6 and 6.2 Gy in Plan_ RA15. Variations of the mean dose to the duodenum, kidneys, and stomach were statistically insignificant. RA and HT can both deliver conformal dose distributions to target volumes while limiting the dose to surrounding OARs in the treatment of pancreatic cancer. Dosimetric advantages might be gained by using RA over HT by reducing the dose to OARs and total MUs used for treatment.",
keywords = "Pancreatic cancer, RapidArc, Tomotherapy",
author = "Jing Cai and Jinbo Yue and Robert McLawhorn and Wensha Yang and Krishni Wijesooriya and Dunlap, {Neal E.} and Ke Sheng and Yin, {Fang Fang} and Benedict, {Stanley H}",
year = "2011",
doi = "10.1016/j.meddos.2010.07.002",
language = "English (US)",
volume = "36",
pages = "317--320",
journal = "Medical Dosimetry",
issn = "0958-3947",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Dosimetric Comparison of 6 MV and 15 MV Single Arc Rapidarc to Helical TomoTherapy for the Treatment of Pancreatic Cancer

AU - Cai, Jing

AU - Yue, Jinbo

AU - McLawhorn, Robert

AU - Yang, Wensha

AU - Wijesooriya, Krishni

AU - Dunlap, Neal E.

AU - Sheng, Ke

AU - Yin, Fang Fang

AU - Benedict, Stanley H

PY - 2011

Y1 - 2011

N2 - We conducted a planning study to compare Varian's RapidArc (RA) and helical TomoTherapy (HT) for the treatment of pancreatic cancer. Three intensity-modulated radiotherapy (IMRT) plans were generated for 8 patients with pancreatic cancer: one using HT with 6-MV beam (Plan_ HT6), one using single-arc RA with 6-MV beam (Plan_ RA6), and one using single-arc RA with 15-MV beam (Plan_ RA15). Dosimetric indices including high/low conformality index (CI 100%/CI 50%), heterogeneity index (HI), monitor units (MUs), and doses to organs at risk (OARs) were compared. The mean CI 100% was statistically equivalent with respect to the 2 treatment techniques, as well as beam energy (0.99, 1.01, and 1.02 for Plan_ HT6, Plan_ RA6, and Plan_ RA156, respectively). The CI 50% and HI were improved in both RA plans over the HT plan. The RA plans significantly reduced MU (MU RA6 = 697, MU RA15 = 548) compared with HT (MU HT6 = 6177, p = 0.008 in both cases). The mean maximum cord dose was decreased from 29.6 Gy in Plan_ HT6 to 21.6 Gy (p = 0.05) in Plan_ RA6 and 21.7 Gy (p = 0.04) in Plan_ RA15. The mean bowel dose decreased from 17.2 Gy in Plan_ HT6 to 15.2 Gy (p = 0.03) in Plan_ RA6 and 15.0 Gy (p = 0.03) Plan_ RA15. The mean liver dose decreased from 8.4 Gy in Plan_ HT6 to 6.3 Gy (p = 0.04) in Plan_ RA6 and 6.2 Gy in Plan_ RA15. Variations of the mean dose to the duodenum, kidneys, and stomach were statistically insignificant. RA and HT can both deliver conformal dose distributions to target volumes while limiting the dose to surrounding OARs in the treatment of pancreatic cancer. Dosimetric advantages might be gained by using RA over HT by reducing the dose to OARs and total MUs used for treatment.

AB - We conducted a planning study to compare Varian's RapidArc (RA) and helical TomoTherapy (HT) for the treatment of pancreatic cancer. Three intensity-modulated radiotherapy (IMRT) plans were generated for 8 patients with pancreatic cancer: one using HT with 6-MV beam (Plan_ HT6), one using single-arc RA with 6-MV beam (Plan_ RA6), and one using single-arc RA with 15-MV beam (Plan_ RA15). Dosimetric indices including high/low conformality index (CI 100%/CI 50%), heterogeneity index (HI), monitor units (MUs), and doses to organs at risk (OARs) were compared. The mean CI 100% was statistically equivalent with respect to the 2 treatment techniques, as well as beam energy (0.99, 1.01, and 1.02 for Plan_ HT6, Plan_ RA6, and Plan_ RA156, respectively). The CI 50% and HI were improved in both RA plans over the HT plan. The RA plans significantly reduced MU (MU RA6 = 697, MU RA15 = 548) compared with HT (MU HT6 = 6177, p = 0.008 in both cases). The mean maximum cord dose was decreased from 29.6 Gy in Plan_ HT6 to 21.6 Gy (p = 0.05) in Plan_ RA6 and 21.7 Gy (p = 0.04) in Plan_ RA15. The mean bowel dose decreased from 17.2 Gy in Plan_ HT6 to 15.2 Gy (p = 0.03) in Plan_ RA6 and 15.0 Gy (p = 0.03) Plan_ RA15. The mean liver dose decreased from 8.4 Gy in Plan_ HT6 to 6.3 Gy (p = 0.04) in Plan_ RA6 and 6.2 Gy in Plan_ RA15. Variations of the mean dose to the duodenum, kidneys, and stomach were statistically insignificant. RA and HT can both deliver conformal dose distributions to target volumes while limiting the dose to surrounding OARs in the treatment of pancreatic cancer. Dosimetric advantages might be gained by using RA over HT by reducing the dose to OARs and total MUs used for treatment.

KW - Pancreatic cancer

KW - RapidArc

KW - Tomotherapy

UR - http://www.scopus.com/inward/record.url?scp=79960929367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960929367&partnerID=8YFLogxK

U2 - 10.1016/j.meddos.2010.07.002

DO - 10.1016/j.meddos.2010.07.002

M3 - Article

VL - 36

SP - 317

EP - 320

JO - Medical Dosimetry

JF - Medical Dosimetry

SN - 0958-3947

IS - 3

ER -